Bush Administration Considering Physician Ratings

Publication
Article
OncologyONCOLOGY Vol 15 No 7
Volume 15
Issue 7

Thomas Scully, the new administrator of the Health Care Financing Administration, is moving fast to make improvements to Medicare. A proposal to collect and publish quality and outcome information on health-care practitioners who treat

Thomas Scully, the new administrator of the Health CareFinancingAdministration, is moving fast to make improvements to Medicare.A proposal to collect and publish quality and outcome information on health-carepractitioners who treat Medicare patients will apparently be included in apackage of reforms that Mr. Scully plans to unveil.

In a speech at the USChamber of Commerce, Mr. Scully said he had a mandate to "shake up"the agency. He said the Bush administration would give the elderly moreinformation on their health insurance options, and publicize data on the qualityof care provided by hospitals, doctors, nursing homes, and home care agencies.

Sen. Bill Frist (R-Tenn), formerly a practicing physician, welcomed the overhaulbut said the administration must be careful to include hospitals and others inthe deliberations. "We need to make sure that we don’t unduly increasethe burdens on doctors and health-care providers who already face increasingregulatory constraints,’’ he said. Mr. Scully has not disclosed what kind ofratings system he has in mind.

Experiments with physician systems in Portland,Oregon, and Cincinnati, Ohio, have left some physicians exasperated. NationalResearch Corp, headquartered in Lincoln, Nebraska, rated primary care physiciansin those two cities in four areas of "care." Health plans in thosecities provided the names of patients and physicians.

"Our response was, it’sworthless," said Jim Kronenberg, associate executive director of thePortland-based Oregon Medical Association. "It’s got this sort of MickeyMouse seal of approval without any real hard data."

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
Related Content